In 2036, investors will regret not loading up on this multibagger in the making

Regeneron's science and its Dupixent revenue are paving the way for it to further expand its portfolio.

Regeneron’s Dupixent Win And Rare Disease Push Reshape Risk Reward Profile

Regeneron Pharmaceuticals (NasdaqGS:REGN) received FDA approval for Dupixent as the first treatment for allergic fungal rhinosinusitis in both adults and children. The FDA also accepted garetosmab for ...
Business Insider

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis

Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study ...

Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the top gene therapy stocks to buy according to hedge funds. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on February 24 that the U.S ...

Regeneron, Sanofi Get FDA Approval For Dupixent in Allergic Fungal Rhinosinusitis

Regeneron Pharmaceuticals and Sanofi have won U.S. Food and Drug Administration expanded approval of their blockbuster anti-inflammatory drug Dupixent for certain patients with allergic fungal ...

Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment

Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms ...

Dupixent Approvals Expand Regeneron’s Immunology Reach And Valuation Debate

Regeneron Pharmaceuticals (NasdaqGS:REGN) and Sanofi received FDA approval for Dupixent to treat allergic fungal ...
Pharmabiz

Regeneron-Sanofi’s Dupixent recommended by CHMP for EU approval to treat CSU in young children with ongoing symptoms despite treatment

Regeneron-Sanofi’s Dupixent recommended by CHMP for EU approval to treat CSU in young children with ongoing symptoms despite treatment: Tarrytown, New York Wednesday, March 4, 2 ...